Results 81 to 90 of about 311,881 (293)
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective To determine the concentration of glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF) and plasma in Alexander disease (AxD) and whether GFAP levels are predictive of disease phenotypes. Methods CSF and plasma were collected (longitudinally when available) from AxD participants and non‐AxD controls.
Amy T. Waldman +9 more
wiley +1 more source
Tumor Biology, 2017 Acute myeloid leukemia is characterized by its high biological and clinical heterogeneity, which represents an important barrier for a precise disease classification and accurate therapy.
Alberto Ponciano-Gómez +5 more
doaj +1 more source
Біологічні студії, 2014 The exposition of α1-acid glycoprotein and fibronectin on the surface and inside the lymphocytes of healthy donors and hematological patients with acute and chronic myeloid leukemia were studied.
G. S. Маslak
doaj +1 more source
No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML 10 and 12 trials [PDF]
, 2005 Fetal liver tyrosine kinase 3 (FLT3) internal tandem duplications (ITDs) are powerful adverse prognostic indicators for relapse in acute myelold leukemia (AML) but the most efficacious therapy for FLT3/ ITD+ patients is currently unknown.
Burnett, AK +6 more
core
p53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia [PDF]
, 2011 Suppression of apoptosis by TP53 mutation contributes to resistance of acute myeloid leukemia (AML) to conventional cytotoxic treatment. Using differentiation to induce irreversible cell cycle exit in AML cells could be a p53-independent treatment ...
Anjali Advani +15 more
core +2 more sources
Advanced Healthcare Materials, EarlyView.We developed a novel copper‐doped aluminum nano‐adjuvant (CuNA) to overcome cytarabine resistance in acute myeloid leukemia (AML). CuNA effectively sensitizes drug‐resistant AML cells to cytarabine by inducing mitochondrial dysfunction and inhibiting HMGCR/GPX4 to amplify ferroptosis.
Chao He +10 more
wiley +1 more source
Azacitidine as salvage therapy for acute myeloid leukemia in a severely ill patient
Hematology Reports, 2014 Acute myeloid leukemia (AML) is a hematological malignancy of myeloid progenitor cells that disrupt normal hematopoiesis. Current chemotherapy regimens result in complete remission in many cases; however, there exists no standard efficacious therapy for ...
Harry Ross Powers +4 more
doaj +1 more source
Imipramine blue sensitively and selectively targets FLT3-ITD positive acute myeloid leukemia cells. [PDF]
, 2017 Aberrant cytokine signaling initiated from mutant receptor tyrosine kinases (RTKs) provides critical growth and survival signals in high risk acute myeloid leukemia (AML).
Arbiser, Jack L +6 more
core +1 more source
Advanced Healthcare Materials, EarlyView.The image shows a schematic form a nanobody‐conjugated theranostic prodrug (NBD) platform targeting tumor‐associated αvβ3 integrin. The NBD system integrates selective nanobody‐mediated tumor recognition, glutathione‐responsive disulfide cleavage for doxorubicin release, and aza‐BODIPY‐based near‐infrared fluorescence for real‐time imaging.
Sanu Karan +13 more
wiley +1 more source
Haematologica, 2014 Acute myeloid leukemia with t(6;9)(p22;q34) is listed as a distinct entity in the 2008 World Health Organization classification, but little is known about the clinical implications of t(6;9)-positive myeloid leukemia in children.
Julie Damgaard Sandahl +27 more
doaj +1 more source